A new study has discovered a promising approach to improve the efficacy of adoptive cell therapies for cancer. The research, published in Molecular Therapy: Nucleic Acids, describes the development of novel Fas-TNFR chimeras acting as decoys for the Fas ligand and preventing it from binding to its natural receptor on the surface of chimeric antigen receptor (CAR) T cells.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the person’s immune system destroys its own pancreatic islet cells that leads to complete loss of insulin production. Allogeneic pancreatic islet cell transplantation has been shown to replenish the vanished β-cell population and provide glycemic control, restoration of hypoglycemia awareness, and protection from severe hypoglycemic events. However, with allogeneic transplantation, there is a need for life-long immunosuppression to protect the islet grafts from allo- and autoimmunity.
Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.
Over half of the children with high-risk neuroblastoma experience late relapses caused by minimal residual disease. Since chimeric antigen receptor (CAR) T-cell therapy has shown efficacy against minimal residual disease in pediatric patients with hematologic malignancies, several CAR T-cell therapies are being investigated for neuroblastoma.
Mesothelin (MSLN) glycoprotein is overexpressed in many solid tumors and is considered a relevant target for antigen-specific therapies. In fact, chimeric antigen receptor (CAR) T-cell therapy against MSLN has shown promising results in preclinical models, as well as safety in a phase I trial.
Researchers from Caribou Biosciences Inc. presented preclinical data for the novel BCMA-specific allogeneic CAR T-cell therapy candidate, CB-011, being developed for the treatment of relapsed or refractory multiple myeloma. A genome editing strategy was implemented in the production of CB-011 to blunt CAR T-cell rejection by both patient T cells and natural killer (NK) cells.
Researchers from Institut d'Investigacions Biomèdiques August Pi i Sunyer and affiliated organizations have reported the development of novel dual CD19/BCMA CAR T cells, referred to as ARI-0003, developed through co-transduction of two lentiviral vectors encoding CARs targeting CD19 (ARI-0001) and BCMA (ARI-0002h).
Coeptis Therapeutics Holdings Inc. has entered into a sponsored research agreement with the University of Pittsburgh to advance preclinical development of SNAP-CAR T cells targeting HER2, and to explore opportunities to expand the applicability of SNAP-CAR in oncology.
Sana Biotechnology Inc. has received FDA clearance of its IND application to initiate a first-in-human study of SC-291 in patients with various B-cell malignancies. Initial clinical data from the study are expected later this year. SC-291 is a CD19-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy developed using Sana's hypoimmune platform.
RSS
